skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Preconception Counseling and Care for HIV-Infected Women of Childbearing Age

Overview

(Last updated: August 6, 2015; last reviewed: August 6, 2015)

Panel's Recommendations

Panel's Recommendations

  • Discuss childbearing intentions with all women of childbearing age on an ongoing basis throughout the course of their care (AIII).
  • Provide information about effective and appropriate contraceptive methods to reduce the likelihood of unintended pregnancy (AI).
  • During preconception counseling, include information on safer sexual practices and elimination of alcohol, illicit drugs, and smoking (AII).
  • All HIV-infected women contemplating pregnancy should be receiving combination antiretroviral therapy (cART) and have a plasma viral load below the limit of detection prior to conception (AII)
  • When selecting or evaluating cART for HIV-infected women of childbearing age, consider a regimen’s effectiveness, a woman’s hepatitis B status, teratogenic potential of the drugs in the cART regimen, and possible adverse outcomes for the mother and fetus (AII).
  • HIV infection does not preclude the use of any contraceptive method (AII). However, drug-drug interactions between hormonal contraceptives and cART should be taken into account. 
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Overview 

The Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists, and other national organizations recommend offering all women of childbearing age comprehensive family planning and the opportunity to receive preconception counseling and care as a component of routine primary medical care. The purpose of preconception care is to improve the health of each woman before conception by identifying risk factors for adverse maternal or fetal outcomes, providing education and counseling targeted to patients’ individual needs, and treating or stabilizing medical conditions to optimize maternal and fetal outcomes.1 Preconception care is not something that occurs in a single clinical visit but, rather, a process of ongoing care and interventions integrated into primary care to address the needs of women during the different stages of reproductive life. Because more than half of all pregnancies in the United States are unintended2-8 it is important that comprehensive family planning and preconception care be integrated into routine health visits. Providers should initiate and document a nonjudgmental conversation with all women of reproductive age concerning their reproductive desires because women may be reluctant to bring this up themselves.9-12 HIV care providers who routinely care for women of reproductive age play an important role in promoting preconception health and informed reproductive decisions.

The fundamental principles of preconception counseling and care are outlined in the CDC Preconception Care Work Group’s Recommendations to Improve Preconception Health and Health Care. In addition to the general components of preconception counseling and care that are appropriate for all women of reproductive age, HIV-infected women have specific needs that should be addressed.13-16 Because many HIV-infected women are aware of their HIV status before becoming pregnant, issues that impact pregnancy can be addressed before conception during their routine medical care for HIV disease. In addition to the principles outlined by the CDC Preconception Care Work Group,17 the following components of preconception counseling and care are specifically recommended for HIV-infected women. Health care providers should:

  • Discuss reproductive options, actively assess women’s pregnancy intentions on an ongoing basis throughout the course of care, and, when appropriate, make referrals to experts in HIV and women’s health, including experts in reproductive endocrinology and infertility when necessary.18,19
  • Counsel on safe sexual practices (including condoms) that prevent HIV transmission to sexual partners, protect women from acquiring sexually transmitted diseases, and reduce the potential to acquire more virulent or resistant strains of HIV.
  • Counsel on eliminating alcohol, illicit drug use, and cigarette smoking.
  • Counsel women contemplating pregnancy to take a daily multivitamin that contains 400 mcg of folic acid to help prevent certain birth defects.
  • Educate and counsel women about risk factors for perinatal transmission of HIV, strategies to reduce those risks, potential effects of HIV or of antiretroviral (ARV) drugs given during pregnancy on pregnancy course and outcomes, and the recommendation that HIV-infected women in the United States not breastfeed because of the risk of transmission of HIV to their infants and the availability of safe and sustainable infant feeding alternatives.
  • When prescribing combination antiretroviral therapy (cART) to women of childbearing age, consider the regimen’s effectiveness, an individual’s hepatitis B status, the potential for teratogenicity, and possible adverse outcomes for mother and fetus.20-22
  •  Use the preconception period in women who are contemplating pregnancy to adjust cART to exclude efavirenz or other drugs with teratogenic potential.
  • Make a primary treatment goal for women who are on cART and who are planning a pregnancy to attain a sustained suppression of plasma viral load below the limit of detection prior to conception to decrease the risk of perinatal transmission and of HIV transmission to an uninfected partner.
  • Evaluate and manage therapy-associated side effects such as hyperglycemia, anemia, and hepatotoxicity that may adversely impact maternal-fetal health outcomes.
  • Evaluate the need for prophylaxis or treatment of opportunistic infections, considering the safety, tolerability, and potential toxicity of specific agents when used in pregnancy (see Pediatric OI Guidelines and Adult OI Guidelines).
  • Administer influenza, pneumococcal, hepatitis A, hepatitis B, Tdap, and other vaccines as indicated (see http://www.cdc.gov/vaccines/acip/committee/guidance/rec-vac-preg.html and 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host). 
  • Encourage sexual partners to receive counseling and HIV testing and, if infected, to seek HIV care.
  • Offer all women who do not desire pregnancy effective and appropriate contraceptive methods to reduce the likelihood of unintended pregnancy. HIV-infected women can use all available contraceptive methods, including hormonal contraception (e.g., pill, patch, ring, injection, implant) and intrauterine devices (IUDs).23 Providers should be aware of potential interactions between ARV drugs and hormonal contraceptives that could lower contraceptive efficacy (see Table 3 below).
  • Offer emergency contraception as appropriate, including emergency contraceptive pills and the copper IUD. Concerns about drug interactions between ARVs and emergency contraceptive pills containing estrogen and a progestin, or containing levonorgestrel only, may be similar to concerns when those formulations are used for regular contraception.24 There are no data on potential interactions between ARVs and ulipristal acetate, a progesterone receptor modulator; however, ulipristal acetate is predominantly metabolized by CYP3A4, so interactions can be expected.

A World Health Organization expert group reviewed all available evidence regarding hormonal contraception and HIV transmission to an uninfected partner and recommended that women living with HIV can continue to use all existing hormonal contraceptive methods without restriction.25 However, drug-drug interactions between hormonal contraceptives and cART should be taken into account (see Table 3).

Data on drug interactions between ARV agents and hormonal contraceptives primarily come from drug labels and limited studies,24,26-38 and the clinical implications have not been well studied. The magnitude of changes in contraceptive drug levels that may reduce contraceptive efficacy or increase contraceptive-associated adverse effects is unknown. In a study of 570 HIV-infected women in Swaziland using Jadelle implants, none of the women on nevirapine or ritonavir-boosted lopinavir-based regimens (n = 208 and 13, respectively) became pregnant, whereas 15 women on efavirenz (n = 121; 12.4%) became pregnant.37 Hormonal contraceptives can be used with cART in women without other contraindications. Additional or alternative methods of contraception may be recommended when drug interactions are known. For women using ritonavir-boosted protease inhibitors who are on combination hormonal contraceptives (e.g., pills, patches, rings) or progestin-only pills, use of an alternative or additional method of contraception is recommended. Implants generally can be used, but providers may also consider use of an alternative method or recommend the additional use of a reliable barrier method. Depot medroxyprogesterone acetate (DMPA) can be used without restriction because of its relatively higher dose and limited studies that have shown no significant interaction between DMPA and ARVs.27,29 

Because no high-quality, definitive studies exist on pregnancy rates among women on different hormonal contraceptives and ARVs, the dosing recommendations in Table 3 are based on consensus expert opinion. Whenever possible, the recommendations are based on available data regarding pharmacokinetic (PK) interactions between ARVs and combined hormonal methods, DMPA and etonogestrel implants. The lowest decreases in PK for which an alternative method was recommended was 14% in norethindrone (with ritonavir-boosted darunavir) and 19% in ethinyl estradiol (ritonavir-boosted atazanavir). For women using atazanavir without ritonavir boosting (ethinyl estradiol increase 48%, norethindrone increase 110%), the Panel recommends use of oral contraceptives containing ≤30 µg ethinyl estradiol. The Panel did not recommend any change in ethinyl estradiol dose for etravirine (ethinyl estradiol increase 22%), rilpivirine (ethinyl estradiol increase 14%), or indinavir (ethinyl estradiol increase 25%, norethindrone increase 26%).

All recommendations in the following table are based on consensus expert opinion.

Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives (CIII).
ARV Drug
Effect on Contraceptive Drug Levels Dosing Recommendation/Clinical Comment for Combined Hormonal Methods and Progestin-Only  Dosing Recommendation/
Clinical Comment for DMPAa
Dosing Recommendation/
Clinical Comment for Etonogestrel Implants 
NNRTIs
EFV Oral Ethinyl Estradiol/Norgestimate:
  • No effect on ethinyl estradiol concentrations
  • ↓ active metabolites of norgestimate (levonorgestrel AUC ↓ 83%; norelgestromin AUC ↓ 64%)
Implant:
  • ↓ etonogestrel
Levonorgestrel (Emergency contraception) AUC ↓ 58%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Use alternative or additional contraceptive method.
ETR Ethinyl estradiol AUC ↑ 22%

Norethindrone
  • No significant effect
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
NVP Ethinyl estradiol AUC ↓ 20%

Norethindrone AUC ↓ 19%

DMPA
  • No significant change
Can consider an alternative method or a reliable method of barrier contraception in addition to this method.
No additional contraceptive protection is needed.  Can consider an alternative method or a reliable method of barrier contraception in addition to this method.
RPV Ethinyl estradiol AUC ↑ 14%

Norethindrone
  • No significant change
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
RTV-Boosted PIs
ATV/r Ethinyl estradiol AUC ↓ 19%

Norgestimate AUC ↑ 85%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
DRV/r Ethinyl estradiol AUC ↓ 44%

Norethindrone AUC ↓ 14%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
FPV/r Ethinyl estradiol AUC ↓ 37%

Norethindrone AUC ↓ 34%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
LPV/r Ethinyl estradiol AUC ↓ 42%

Norethindrone AUC ↓ 17%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
SQV/r ↓ Ethinyl estradiol
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
TPV/r Ethinyl estradiol AUC ↓ 48%

Norethindrone:
  • No significant change
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Can consider an alternative method or a reliable method of barrier contraception in addition to this method. 
PIs without RTV
ATV Ethinyl estradiol AUC ↑ 48%

Norethindrone AUC ↑ 110%
No additional contraceptive protection is needed.

Oral contraceptive should contain ≤30 mcg of ethinyl estradiol or use alternative method. 

Oral contraceptives containing <25 mcg ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
FPV Amprenavir
  • ↑ Ethinyl estradiol
  • ↑ Norethindrone
Fosamprenavir with Ethinyl Estradiol/Norethindrone
  • ↓ Amprenavir (AUC 22%, Cmin 20%)
Use alternative contraceptive method.

Use of fosamprenavir alone with ethinyl estradiol/norethindrone may lead to loss of virologic response.
No additional contraceptive protection is needed.
Use alternative or additional contraceptive method.
IDV Ethinyl estradiol AUC ↑ 25%

Norethindrone AUC ↑ 26%
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
NFV Ethinyl estradiol AUC ↓ 47%

Norethindrone AUC ↓ 18%
Use alternative or additional contraceptive method.
No additional contraceptive protection is needed.
Use alternative or additional contraceptive method.
CCR5 Antagonist
MVC No significant effect on ethinyl estradiol or levonorgestrel
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
Integrase Inhibitor
RAL
No significant effect
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
DTG No significant effect on norgestimate or ethinyl estradiol
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
EVG/COBI Norgestimate AUC ↑ 226%

Ethinyl estradiol AUC ↓ 75%
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
No additional contraceptive protection is needed.
a Because the hormonal levels achieved with DMPA are substantially higher than are required for contraception, any small reduction in hormonal level due to ARVs is unlikely to reduce contraceptive effectiveness.

Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; ATV/r = ritonavir-boosted atazanavir; AUC = area under the curve; Cmin = minimum plasma concentration; COBI = cobicistat; DMPA = depot medroxyprogesterone acetate; DRV/r = ritonavir-boosted darunavir; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FPV = fosamprenavir; FPV/r = ritonavir-boosted fosamprenavir; IDV = indinavir; LPV/r = ritonavir-boosted lopinavir; MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SQV/r = ritonavir-boosted saquinavir; TPV/r = ritonavir-boosted tipranavir

Source: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Tables 15a, 15b, and 15d. Accessed May 15, 2015. 

References 

  1. American College of O, Gynecologists. ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women's health care. Obstet Gynecol. 2005;106(3):665-666. Available at http://www.ncbi.nlm.nih.gov/pubmed/16135611.
  2. Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep. 2006;55(RR-6):1-23. Available at http://www.ncbi.nlm.nih.gov/pubmed/16617292.
  3. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS. 2008;22(1):29-40. Available at http://www.ncbi.nlm.nih.gov/pubmed/18442305.
  4. Elgalib A, Hegazi A, Samarawickrama A, et al. Pregnancy in HIV-infected teenagers in London. HIV Med. 2011;12(2):118-123. Available at http://www.ncbi.nlm.nih.gov/pubmed/20807252.
  5. Kost K, Finer LB, Singh S. Variation in state unintended pregnancy rates in the United States. Perspect Sex Reprod Health. 2012;44(1):57-64. Available at http://www.ncbi.nlm.nih.gov/pubmed/22405153.
  6. Sun M, Peipert JF, Zhao Q, et al. Trends in contraceptive use among women with human immunodeficiency virus. Obstet Gynecol. 2012;120(4):783-790. Available at http://www.ncbi.nlm.nih.gov/pubmed/22996095.
  7. Sutton MY, Patel R, Frazier EL. Unplanned pregnancies among HIV-infected women in care-United States. J Acquir Immune Defic Syndr. 2014;65(3):350-358. Available at http://www.ncbi.nlm.nih.gov/pubmed/24189153.
  8. Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001-2008. Am J Pub Health. 2014;104 Suppl 1:S43-48. Available at http://www.ncbi.nlm.nih.gov/pubmed/24354819.
  9. Finocchario-Kessler S, Dariotis JK, Sweat MD, et al. Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS. 2010;24(5):317-323. Available at http://www.ncbi.nlm.nih.gov/pubmed/20482467.
  10. Finocchario-Kessler S, Sweat MD, Dariotis JK, et al. Childbearing motivations, pregnancy desires, and perceived partner response to a pregnancy among urban female youth: does HIV-infection status make a difference? AIDS Care. 2012;24(1):1-11. Available at http://www.ncbi.nlm.nih.gov/pubmed/21777077.
  11. Finger JL, Clum GA, Trent ME, Ellen JM, Adolescent Medicine Trials Network for HIVAI. Desire for pregnancy and risk behavior in young HIV-positive women. AIDS Patient Care STDS. 2012;26(3):173-180. Available at http://www.ncbi.nlm.nih.gov/pubmed/22482121.
  12. Rahangdale L, Stewart A, Stewart RD, et al. Pregnancy intentions among women living with HIV in the United States. J Acquir Immune Defic Syndr. 2014;65(3):306-311. Available at http://www.ncbi.nlm.nih.gov/pubmed/24525467.
  13. Lampe MA. Human immunodeficiency virus-1 and preconception care. Matern Child Health J. 2006;10(5 Suppl):S193-195. Available at http://www.ncbi.nlm.nih.gov/pubmed/16832609.
  14. Aaron EZ, Criniti SM. Preconception health care for HIV-infected women. Top HIV Med. 2007;15(4):137-141. Available at http://www.ncbi.nlm.nih.gov/pubmed/17721000.
  15. Anderson J. Women and HIV: motherhood and more. Curr Opin Infect Dis. 2012;25(1):58-65. Available at http://www.ncbi.nlm.nih.gov/pubmed/22156896.
  16. Jones D, Chakhtoura N, Cook R. Reproductive and maternal healthcare needs of HIV infected women. Curr HIV/AIDS Rep. 2013;10(4):333-341. Available at http://www.ncbi.nlm.nih.gov/pubmed/23918674.
  17. Centers for Disease Control and Prevention, et al. Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2003;52(RR-12):1-24. Available at http://www.ncbi.nlm.nih.gov/pubmed/12875251.
  18. Gosselin JT, Sauer MV. Life after HIV: examination of HIV serodiscordant couples' desire to conceive through assisted reproduction. AIDS Behav. 2011;15(2):469-478. Available at http://www.ncbi.nlm.nih.gov/pubmed/20960049.
  19. Finocchario-Kessler S, Sweat MD, Dariotis JK, et al. Understanding high fertility desires and intentions among a sample of urban women living with HIV in the United States. AIDS Behav. 2010;14(5):1106-1114. Available at http://www.ncbi.nlm.nih.gov/pubmed/19908135.
  20. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195-1201. Available at http://www.ncbi.nlm.nih.gov/pubmed/16586354.
  21. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863-1870. Available at http://www.ncbi.nlm.nih.gov/pubmed/12063370.
  22. Stek AM. Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep. 2009;6(2):68-76. Available at http://www.ncbi.nlm.nih.gov/pubmed/19358777.
  23. Centers for Disease C, Prevention. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep. 2012;61(24):449-452. Available at http://www.ncbi.nlm.nih.gov/pubmed/22717514.
  24. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012;2012:137192. Available at http://www.ncbi.nlm.nih.gov/pubmed/22536010.
  25. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and living with HIV: 2014 guidance statment. 2014. Available at http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf?ua=1. Accessed May 15, 2015.
  26. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010;55(4):473-482. Available at http://www.ncbi.nlm.nih.gov/pubmed/20842042.
  27. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007;81(2):222-227. Available at http://www.ncbi.nlm.nih.gov/pubmed/17192768.
  28. Hoyt MJ, Storm DS, Aaron E, Anderson J. Preconception and contraceptive care for women living with HIV. Infect Dis Obstet Gynecol. 2012;2012:604183. Available at http://www.ncbi.nlm.nih.gov/pubmed/23097595.
  29. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. 2008;90(4):965-971. Available at http://www.ncbi.nlm.nih.gov/pubmed/17880953.
  30. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149-156. Available at http://www.ncbi.nlm.nih.gov/pubmed/21447863.
  31. Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol. 2012;2012:890160. Available at http://www.ncbi.nlm.nih.gov/pubmed/22927715.
  32. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin Drug Metab Toxicol. 2013;9(5):559-72. Available at http://www.ncbi.nlm.nih.gov/pubmed/23425052.
  33. Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when co-administered with combined oral contraceptives. J Acquir Immune Defic Syndr. 2013;62(5):534-9. Available at http://www.ncbi.nlm.nih.gov/pubmed/23187949.
  34. Atrio J, Stanczyk FZ, Neely M, Cherala G, Kovacs A, Mishell DR, Jr. Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(1):72-77. Available at http://www.ncbi.nlm.nih.gov/pubmed/24025339.
  35. Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Hoetelmans RM. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(2):118-128. Available at http://www.ncbi.nlm.nih.gov/pubmed/24161160.
  36. Landolt NK, Phanuphak N, Ubolyam S, et al. Significant Decrease of Ethinylestradiol With Nevirapine, and of Etonogestrel With Efavirenz in HIV-Positive Women. J Acquir Immune Defic Syndr. 2014;66(2):e50-52. Available at http://www.ncbi.nlm.nih.gov/pubmed/24608892.
  37. Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN. Implementing the Jadelle implant for women living with HIV in a resource-limited setting in sub-Saharan Africa: concerns for drug interactions leading to unintended pregnancies. AIDS. 2014. Available at http://www.ncbi.nlm.nih.gov/pubmed/24401645.
  38. Thurman AR, Anderson S, Doncel GF. Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol. 2014;71(6):523-530. Available at http://www.ncbi.nlm.nih.gov/pubmed/24521428.

Back to Top